Tempest Therapeutics, Inc. (TPST) Financial Ratios
13 years of historical data (2012–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
2.87
↓-40% vs avg
5yr avg: 4.78
30Y Low0.0·High18.1
ROE
↓
-182.3%
↑-39% vs avg
5yr avg: -131.0%
30Y Low-182%·High-44%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TPST Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Tempest Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $55M | $303M | $68M | $13M | $2M | $1M | $92M | $12M | $367920 | $49M | $265M |
| Enterprise Value | $40M | $288M | $49M | $4M | $-31752553 | $-15379159 | $33M | $-60460032 | $-16482080 | $5M | $221M |
| P/E Ratio → | -1.31 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | 1.25 | 75.32 | 955.30 |
| P/B Ratio | 2.87 | 15.83 | 2.53 | 0.73 | 0.04 | — | 1.54 | 0.17 | 0.02 | 0.45 | 2.09 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
TPST EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | -55.87 | 8.05 | 798.55 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
TPST Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -182.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | 90.5% | -727.1% | -711.9% |
| Operating Margin | — | — | — | — | — | — | — | — | -6943.1% | -12406.1% | -25992.4% |
| Net Profit Margin | — | — | — | — | — | — | — | — | -28670.5% | -12597.2% | -26432.9% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -182.3% | -182.3% | -131.4% | -131.7% | -78.4% | — | -67.0% | -61.7% | -137.3% | -70.0% | -80.4% |
| ROA | -89.9% | -89.9% | -60.4% | -59.9% | -58.9% | -39.1% | -56.0% | -52.3% | -118.8% | -63.0% | -71.7% |
| ROIC | -507.5% | -507.5% | -254.4% | -439.6% | — | — | -5474.2% | -8335.1% | -47.8% | -82.3% | -81.6% |
| ROCE | -121.0% | -121.0% | -72.0% | -75.3% | -74.1% | -47.0% | -66.4% | -51.4% | -32.8% | -68.5% | -78.8% |
TPST Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $30M exceeds total debt of $15M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.80 | 0.80 | 0.77 | 1.22 | 0.51 | — | 0.08 | 0.01 | 0.05 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.78 | -0.69 | -0.50 | -0.92 | — | -0.99 | -1.00 | -1.12 | -0.41 | -0.34 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -31.93 | -31.93 | -20.12 | -21.41 | -21.05 | — | — | -172.51 | — | -122.93 | -165.14 |
Net cash position: cash ($30M) exceeds total debt ($15M)
TPST Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Tempest Therapeutics, Inc.'s current ratio of 2.21x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 4.53x to 2.21x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.21 | 2.21 | 4.29 | 4.53 | 3.44 | 6.15 | 5.68 | 8.50 | 4.82 | 8.82 | 11.55 |
| Quick Ratio | 2.21 | 2.21 | 4.29 | 4.53 | 3.44 | 6.15 | 5.68 | 8.50 | 4.82 | 8.82 | 11.55 |
| Cash Ratio | 2.13 | 2.13 | 4.17 | 4.29 | 2.59 | 5.84 | 5.07 | 7.92 | 16.43 | 8.66 | 11.28 |
| Asset Turnover | — | — | — | — | — | — | — | — | 0.01 | 0.01 | 0.00 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | 1275.64 | — | — |
TPST Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Tempest Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $28M | $15M | $888378 | $291562 | $31210 | $913782 | $103136 | $1168 | $142879 | $120377 |
Peer Comparison
Compare TPST with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TPSTYou | $55M | -1.3 | — | — | — | — | -182.3% | -507.5% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 AGIO | $2B | -3.9 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 MGNX | $186M | -2.5 | — | — | — | -48.7% | -86.9% | -1879.3% | — |
 CRIS | $76M | -1.0 | — | — | 99.5% | -348.4% | -138.8% | — | — |
 RVMD | $30B | -24.0 | — | — | — | — | -58.1% | -54.3% | — |
 MRK | $277B | 15.4 | 10.7 | 22.4 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
See TPST's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TPST Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TPST vs IMVT
Side-by-side business, growth, and profitability comparison vs Immunovant, Inc..
Start ComparisonTPST — Frequently Asked Questions
Quick answers to the most common questions about buying TPST stock.
What is Tempest Therapeutics, Inc.'s P/E ratio?
Tempest Therapeutics, Inc.'s current P/E ratio is -1.3x. This places it at the 50th percentile of its historical range.
What is Tempest Therapeutics, Inc.'s ROE?
Tempest Therapeutics, Inc.'s return on equity (ROE) is -182.3%. The historical average is -97.2%.
Is TPST stock overvalued?
Based on historical data, Tempest Therapeutics, Inc. is trading at a P/E of -1.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.